Results 81 to 90 of about 6,192 (194)

Vildagliptin-induced hepatotoxicity: A case report

, 2016
Vildagliptin-induced hepatotoxicity: A casereportAuthors: Seydahmet Akin1, Şakir Özgür Keşkek2, Sinan Kazan1, Asli Ocal1, Meh-met Aliustaoglu11Dr. Lutfi Kirdar Kartal Training and Research Hospital, Department of Internal Medi-cine, Istanbul, Turkey ...
Kazan, Sinan, Akin, Seydahmet, Ocal, Asli, Aliustaoğlu, Mehmet, Keşkek, Şakir Özgür   +4 more
core  

Mitigating effects of vildagliptin in experimental diabetes with metabolic syndrome

, 2016
Background: Vildagliptin has multiple beneficial effects reported in isolated studies like anti-diabetic, cardio protective, anti-inflammatory and antioxidant.
Borde, Manjusha K., Mohanty, Ipseeta Ray, Deshmukh, Y. A., Suman, Rajesh Kumar, Maheshwari, Ujwala   +4 more
core   +2 more sources

Mild acute pancreatitis with vildagliptin use

Indian Journal of Endocrinology and Metabolism, 2012
Vildagliptin has not been associated with the development of acute pancreatitis in postmarketing reports except one case report from Sydney, Australia.
Ravikant Saraogi, Ritwika Mallik, Sujoy Ghosh   +2 more
doaj   +1 more source

Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes

, 2014
Matthias Blüher,1 Anja Schweizer,2 Giovanni Bader,2 James E Foley3 1Department of Medicine, University of Leipzig, Leipzig, Germany; 2Novartis Pharma AG, Basel, Switzerland; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA Background ...
Schweizer A, Bader G, Blüher M, Foley JE   +3 more
core  

Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes

, 2011
Contains fulltext : 96512.pdf (Publisher’s version ) (Open Access)OBJECTIVE: To investigate whether the dipeptidyl peptidase-4 inhibitor vildagliptin improves endothelium-dependent vasodilatation in patients with type 2 diabetes ...
van Poppel, P.C., Tack, C.J.J., Pleun C.M. van Poppel, Mihai G. Netea, Smits, P., Netea, M.G., Paul Smits, Cees J. Tack   +7 more
core   +1 more source

Effectiveness and Safety of Vildagliptin Sustained Release in the Management of Type 2 Diabetes Mellitus: Real-World Evidence in Indian Patients [NOVELTY Study]

Drugs - Real World Outcomes
Background and Objective Vildagliptin sustained release (XR), a formulation that provides vildagliptin 100 mg with a once-daily dose administration, is a recent introduction to manage type 2 diabetes mellitus in India.
Rakesh Sahay, Anil Bhansali, Surendra Kumar Sharma, Rahul Iyer, Amarnath Sugumaran, Senthilnathan Mohanasundaram, Jaideep Gogtay   +6 more
doaj   +1 more source

Vildagliptin uygulamasının pankreas adacık hücreleri üzerine etkisi

, 2011
Bu çalışmanın amacı, sıçanlara oral olarak uygulanan vildagliptinin adacık hücreleri üzerine etkilerini araştırmaktır. Sıçanlara 4 gün vildagliptin 100 mg/kg/gün verildikten sonra adacık hücreleri izole edildi.
GÜLBAHAR BÖYÜK
core  

Proteomic changes related to actin cytoskeleton function in the skin of vildagliptin-treated mice [PDF]

Background: Vildagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i) is a widely used type 2 diabetes medication that is associated with an up-to 10-fold increased risk for the development of bullous pemphigoid (BP), an autoimmune skin disease.
Nätynki, Antti, Bergmann, Ulrich, Ohlmeier, Steffen, Tasanen, Kaisa, Kokkonen, Nina, Tuusa, Jussi   +5 more
core   +1 more source

Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers.

, 2009
Vildagliptin is an orally effective, potent, and selective inhibitor of dipeptidyl peptidase IV (DPP-4) that improves glycemic control in patients with type 2 diabetes.
Hu, Pei, Yin, Qi, Deckert-Salva, Fabienne, Liu, Dongyang, He, Yan-Ling, Jiang, Ji, Dole, William, Kjems, Lise   +7 more
core  

Comparative effect of vildagliptin and teneligliptin on HbA1c, glycemic efficacy and insulin sensitivity

, 2017
Background: Vildagliptin, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the availability of endogenous incretin hormones, glucagon-like peptide (GLP-1), and glucose-dependent insulinotropic polypeptide, thereby improving ...
Tushar B. Chudiwal, Chudiwal, Tushar B.
core   +2 more sources